<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249053</url>
  </required_header>
  <id_info>
    <org_study_id>DMR99-IRB-062</org_study_id>
    <nct_id>NCT01249053</nct_id>
  </id_info>
  <brief_title>Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner
      mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is
      associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial
      bioenergetics and mitochondrial networks. The changes in mitochondrial shape and
      mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the
      expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Between January 2006 and December 2008, we will retrospectively enroll 100 consecutive LADC
        patients who were admitted to the Department of Thoracic Surgery of China Medical
        University Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  We will collect paraffin blocked resected lung tissue samples from stage I~IIIa
             non-small cell lung cancer patients (age, 40~80 years old) who received lobectomy of
             the affected lung.

        Exclusion Criteria:

          -  History of uremia, other malignant disease, and liver cirrhosis

          -  History of pneumonia and pulmonary tuberculosis

          -  History of long period of medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fang Hsin Yuan</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsin-Yuan Fang, MD</last_name>
      <phone>+886422052121</phone>
      <phone_ext>1638</phone_ext>
      <email>d93421104@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2010</study_first_posted>
  <last_update_submitted>November 26, 2010</last_update_submitted>
  <last_update_submitted_qc>November 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Fang Hsin-Yuan/Director</name_title>
    <organization>China Medical University Hospital</organization>
  </responsible_party>
  <keyword>OPA1</keyword>
  <keyword>lung adenocarcinomas</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Expression of optic atrophy type 1 (OPA1) protein in lung adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Optic Atrophy</mesh_term>
    <mesh_term>Optic Atrophy, Autosomal Dominant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

